PMID- 18788625
OWN - NLM
STAT- MEDLINE
DCOM- 20100326
LR  - 20171116
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 30
IP  - 4
DP  - 2008 Apr
TI  - [Dendritic cell vaccine modified by murine mAFP gene enhances immunoprotective 
      effect on liver carcinogenesis and tumor development in mice].
PG  - 250-4
AB  - OBJECTIVE: To construct a dendritic cell vaccine transduced by murine 
      alpha-fetoprotein (mAFP) gene, and evaluate its immunoprotective effect on 
      C57BL/6J mice during the induction of hepatocellular carcinoma by 
      diethylnitrosamines, carbon tetrachloride and ethanol. METHODS: Dendritic cells 
      (DCs) were induced and augmented by murine IL-4 and GM-CSF, and transfected by 
      recombinant adenovirus engineered with mAFP gene. Major MHC class I and II, B7.1 
      (CD80), B7.2 (CD86), CD18a, and CD54 molecules on DC were analyzed by FACS. 80 
      C57BL/6J male mice were randomly divided into 4 groups (20 mice per group): 
      Simple DC inoculated group, pAdBM5-mAFP-DC inoculated group, pAdBM5-mAFP plasmid 
      inoculated group, and PBS control group. They were immunized once with 5 x 10(5) 
      DCs (0.1 ml)/mouse administered s. c. in the left flank or 100 mg pAdBMS-mAFP 
      plasmid/mouse administered i. m. in the left tibialis anterior muscle. 
      Inoculation was conducted once a week for 4 weeks after 3 times consecutive 
      immunization initially. At the same time of immunization, DEN/CCl4/ethanol were 
      given to induce hepatocellular carcinoma. Tumor incidence was assessed after 20 
      weeks. RESULTS: A transgenic DC vaccine was successfully constructed and the mAFP 
      transgenic DCs expressed high level molecules of major MHC class I and II , B7.1, 
      B7.2, CD18a, and CD54. After the 20-week induction, the incidence of primary 
      hepatocellular carcinoma (PLC) was 70.0% in simple DC inoculated group, 25.0% in 
      pAdBMS-mAFP-DC inoculated group, 65.0% in pAdBM5-mAFP plasmid inoculated group, 
      and 75.0% in PBS control group. There was a significant difference between group 
      B and other groups (P < 0.05). CONCLUSION: mAFP transgenic DC tumor vaccine 
      inoculation may induce strong immunoprotection against liver carcinogenesis and 
      tumor development and reduce PLC incidence induced by DEN/CCl4/ethanol.
FAU - Xie, Yu-An
AU  - Xie YA
AD  - Biomedicine Research Center of Guangxi Cancer Institute, Nanning 530021, China.
FAU - Kuang, Zhi-Peng
AU  - Kuang ZP
FAU - Liang, An-Min
AU  - Liang AM
FAU - Luo, Xiao-Ling
AU  - Luo XL
FAU - Yang, Fan
AU  - Yang F
FAU - Wu, Ji-Ning
AU  - Wu JN
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (B7-1 Antigen)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Recombinant Proteins)
RN  - 0 (alpha-Fetoproteins)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 3IQ78TTX1A (Diethylnitrosamine)
RN  - 3K9958V90M (Ethanol)
RN  - CL2T97X0V0 (Carbon Tetrachloride)
SB  - IM
MH  - Adenoviridae/*genetics
MH  - Animals
MH  - B7-1 Antigen/metabolism
MH  - *Cancer Vaccines
MH  - Carbon Tetrachloride
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*immunology/metabolism
MH  - Diethylnitrosamine
MH  - Ethanol
MH  - Genetic Vectors
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Histocompatibility Antigens Class II/metabolism
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Liver Neoplasms, Experimental/chemically induced/immunology/*prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Random Allocation
MH  - Recombinant Proteins/genetics/metabolism
MH  - Transfection
MH  - alpha-Fetoproteins/*genetics/metabolism
EDAT- 2008/09/16 09:00
MHDA- 2010/03/27 06:00
CRDT- 2008/09/16 09:00
PHST- 2008/09/16 09:00 [pubmed]
PHST- 2010/03/27 06:00 [medline]
PHST- 2008/09/16 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):250-4.